Zobrazeno 1 - 10
of 553
pro vyhledávání: '"Mitesh J. Borad"'
Autor:
Mason J. Webb, Thanich Sangsuwannukul, Jacob van Vloten, Laura Evgin, Benjamin Kendall, Jason Tonne, Jill Thompson, Muriel Metko, Madelyn Moore, Maria P. Chiriboga Yerovi, Michael Olin, Antonella Borgatti, Mark McNiven, Satdarshan P. S. Monga, Mitesh J. Borad, Alan Melcher, Lewis R. Roberts, Richard Vile
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Although patients benefit from immune checkpoint inhibition (ICI) therapy in a broad variety of tumors, resistance may arise from immune suppressive tumor microenvironments (TME), which is particularly true of hepatocellular carcinoma (HCC).
Externí odkaz:
https://doaj.org/article/3cf0fc38fa494b069051f0ff5e7872c6
Autor:
Dmitriy Zamarin, Diwakar Davar, Adel Samson, Kevin J Harrington, Siddharth Sheth, Eric Tu, Mitesh J Borad, Grace K Dy, Evanthia Galanis, Fernanda Arnaldez, Sandip P Patel, Nicholas Durham, Benedito A Carneiro, Sonia Agrawal, Zhongying Chen, Chunling Fan, Maozhen Gong, Jenny Burton, Kevin Laubscher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 11 (2024)
Background MEDI5395 is a recombinant attenuated Newcastle disease virus engineered to express a human granulocyte-macrophage colony-stimulating factor transgene. Preclinically, MEDI5395 demonstrated broad oncolytic activity, augmented by concomitant
Externí odkaz:
https://doaj.org/article/9b8ca43a8d514a34aab835d920738e15
Publikováno v:
Einstein (São Paulo), Vol 22 (2024)
ABSTRACT Objective Multicancer early detection panels have recently become available to patients with healthcare provider prescriptions and available funds. These tests utilize circulating tumor DNA (ctDNA) to screen more than 50 cancers using a sing
Externí odkaz:
https://doaj.org/article/7ab1086b6c184609beacccbcd5e2e0af
Autor:
Linsey E. Jackson, Jennifer L. Tomlinson, Roberto Alva-Ruiz, Lindsey A. Gregory, Seul Kee Byeon, Amro M. Abdelrahman, Dong-Gi Mun, Caroline W. Grant, Zachary C. Fogarty, Chen Wang, Lewis R. Roberts, Rondell P. Graham, Mitesh J. Borad, Sumera I. Ilyas, Gregory J. Gores, Akhilesh Pandey, Arjun P. Athreya, Rory L. Smoot
Publikováno v:
JHEP Reports, Vol 6, Iss 6, Pp 101068- (2024)
Background & Aims: Metabolomic and lipidomic analyses provide an opportunity for novel biological insights. Cholangiocarcinoma (CCA) remains a highly lethal cancer with limited response to systemic, targeted, and immunotherapeutic approaches. Using a
Externí odkaz:
https://doaj.org/article/2c99399c263347e3bad6c6dcc1769f86
Autor:
Chelsae R. Watters, Oumar Barro, Natalie M. Elliott, Yumei Zhou, Musa Gabere, Elizabeth Raupach, Alexander T. Baker, Michael T. Barrett, Kenneth H. Buetow, Bertram Jacobs, Mahesh Seetharam, Mitesh J. Borad, Bolni Marius Nagalo
Publikováno v:
Molecular Therapy: Oncolytics, Vol 29, Iss , Pp 4-14 (2023)
Vesiculoviruses are attractive oncolytic virus platforms due to their rapid replication, appreciable transgene capacity, broad tropism, limited preexisting immunity, and tumor selectivity through type I interferon response defects in malignant cells.
Externí odkaz:
https://doaj.org/article/0f9b4133faac47bdbaa01ba69e5b9a37
Autor:
Mitesh J Borad
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0308087 (2024)
Rare cancers are defined by low incidence rates, and may lack evidence that supports uniform standards of care and relevant clinical guidelines. Rare cancers may represent up to 24% of all cancers, yet remain understudied and underappreciated in term
Externí odkaz:
https://doaj.org/article/08fe72f0271449d8b9524d932098e540
Autor:
Mitesh J Borad, Giannoula Karagouga, Jun Yin, Stephen Murphy, Paul Baas, James Smadbeck, John Cheville, Alexa McCune, Aaron Mansfield, George Vasmatzis, Aakash P Desai, Farhad Kosari, Maria Disselhorst, Alireza Agahi, Tobias Peikert, Julia Udell, Sarah H Johnson, Janet Schaefer-Klein
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 6 (2023)
Background Immune checkpoint inhibitors (ICIs) are now a first-line treatment option for patients with pleural mesothelioma with the recent approval of ipilimumab and nivolumab. Mesothelioma has a low tumor mutation burden and no robust predictors of
Externí odkaz:
https://doaj.org/article/a6826c67289e41c885adfe1bf7000f0b
Autor:
Ghassan K. Abou-Alfa, Peter R. Galle, Yee Chao, Joseph Erinjeri, Jeong Heo, Mitesh J. Borad, Angelo Luca, James Burke, Adina Pelusio, Delphine Agathon, Monika Lusky, Caroline Breitbach, Shukui Qin, Edward Gane
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Introduction Intratumoral administration of pexa-vec (Pexastimogene Devacirepvec), an oncolytic and immunotherapeutic vaccinia virus. given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses. We
Externí odkaz:
https://doaj.org/article/bdd152f1ab754f309e25b0ec1686e9ea
Autor:
Deepak Thirunavukarasu, Lauren Y. Cheng, Ping Song, Sherry X. Chen, Mitesh J. Borad, Lawrence Kwong, Phillip James, Daniel J. Turner, David Yu Zhang
Publikováno v:
Genome Biology, Vol 22, Iss 1, Pp 1-17 (2021)
Abstract We develop the Oncogene Concatenated Enriched Amplicon Nanopore Sequencing (OCEANS) method, in which variants with low variant allele frequency (VAFs) are amplified and subsequently concatenated for Nanopore Sequencing. OCEANS allows accurat
Externí odkaz:
https://doaj.org/article/4bf551b9432b4350a7d2d7853a93be54
Autor:
Yuguo Zhang, Musa Gabere, Mika A. Taylor, Camila C. Simoes, Chelsae Dumbauld, Oumar Barro, Mulu Z. Tesfay, Alicia L. Graham, Khandoker Usran Ferdous, Alena V. Savenka, Jean Christopher Chamcheu, Charity L. Washam, Duah Alkam, Allen Gies, Stephanie D. Byrum, Matteo Conti, Steven R. Post, Thomas Kelly, Mitesh J. Borad, Martin J. Cannon, Alexei Basnakian, Bolni M. Nagalo
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
It has long been known that oncolytic viruses wield their therapeutic capability by priming an inflammatory state within the tumor and activating the tumor immune microenvironment, resulting in a multifaceted antitumor immune response. Vaccine-derive
Externí odkaz:
https://doaj.org/article/cc4969f03b474994ad64d25b34a6caa6